Steroid-Refractory Immune Related Hepatitis May Hide Viral Re-Activation

Fabrizio Citarella1 Department of Medical Oncology, Campus Bio-Medico UniversityVia Alvaro del Portillo 200, Rome, Italy

https://orcid.org/0000-0003-3096-4452

Alessandro Galletti1 Department of Medical Oncology, Campus Bio-Medico UniversityVia Alvaro del Portillo 200, Rome, ItalyCorrespondence[email protected]

https://orcid.org/0000-0001-7444-2993

Marco Russano1 Department of Medical Oncology, Campus Bio-Medico UniversityVia Alvaro del Portillo 200, Rome, Italy

Paolo Gallo2 Department of Medicine, Unit of Internal Medicine & Hepatology, Campus Bio-Medico UniversityVia Alvaro del Portillo 200, Rome, Italy

Umberto Vespasiani-Gentilucci2 Department of Medicine, Unit of Internal Medicine & Hepatology, Campus Bio-Medico UniversityVia Alvaro del Portillo 200, Rome, Italy

Antonio Picardi2 Department of Medicine, Unit of Internal Medicine & Hepatology, Campus Bio-Medico UniversityVia Alvaro del Portillo 200, Rome, Italy

Giuseppe Tonini1 Department of Medical Oncology, Campus Bio-Medico UniversityVia Alvaro del Portillo 200, Rome, Italy

Bruno Vincenzi1 Department of Medical Oncology, Campus Bio-Medico UniversityVia Alvaro del Portillo 200, Rome, Italy

Daniele Santini1 Department of Medical Oncology, Campus Bio-Medico UniversityVia Alvaro del Portillo 200, Rome, Italy

show all

References

JenningsJJ , MandaliyaR , NakshabandiA , LewisJH. Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies. Expert Opin. Drug Metab. Toxicol.15(3), 231–244 (2019).
PubMed Web of Science ®Google Scholar
ShahNJ , Al-ShboolG , BlackburnMet al.Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection. J. Immunother. Cancer7(1), 353 (2019).
PubMed Web of Science ®Google Scholar
PandeyA , EzemenariS , LiaukovichM , RichardI , BorisA. A rare case of pembrolizumab-induced reactivation of hepatitis B. Case Rep. Oncol. Med. ID 5985131 (2018).
PubMed Web of Science ®Google Scholar
LakeAC. Hepatitis B reactivation in a long-term nonprogressor due to nivolumab therapy. AIDS31(15), 2115–2118 (2017).
PubMed Web of Science ®Google Scholar
KoksalAS , TokaB , EminlerAT , HacibekirogluI , UslanMI , ParlakE. HBV-related acute hepatitis due to immune checkpoint inhibitors in a patient with malignant melanoma. Ann. Oncol.28(12), 3103–3104 (2017).
PubMed Web of Science ®Google Scholar
HaanenJBAG , CarbonnelF , RobertC, ESMO Guidelines Committeeet al.Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol.29(Suppl. 4), iv264–iv266 (2018).
PubMed Web of Science ®Google Scholar

Steroid-Refractory Immune Related Hepatitis May Hide Viral Re-Activation

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Steroid-Refractory Immune Related Hepatitis May Hide Viral Re-Activation

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date